Status:
WITHDRAWN
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Lead Sponsor:
Jeremy Rudnick, M.D
Collaborating Sponsors:
Kairos Pharma
Conditions:
Recurrent Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxici...
Eligibility Criteria
Inclusion
- Recurrent glioblastoma
- HLA-A1 and HLA-A2 positive
- Complete resection of tumor
Exclusion
- Clinically significant pulmonary, cardiac or other systemic disease
- Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed.
- Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition.
- Known history of Hepatitis B or Hepatitis C
- Allergy to Dimethyl sulfoxide (DMSO)
- Allergy to gentamicin
Key Trial Info
Start Date :
June 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2027
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05341947
Start Date
June 1 2026
End Date
December 1 2027
Last Update
October 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048